Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

NCT04190628 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Stopped Not related to safety concerns or lack of efficacy

Conditions

Advanced Solid Tumor
BRAF V600 Mutation

Interventions

DRUG: ABM-1310
DRUG: Cobimetinib

Sponsor

ABM Therapeutics Corporation